Browse > Article
http://dx.doi.org/10.1007/s13206-018-2411-0

Clinical Evaluation of a Low-pain Long Microneedle for Subcutaneous Insulin Injection  

Lee, Ghunil (Department of Biomaterials Science and Engineering, Yonsei University)
Ma, Yonghao (Department of Biotechnology, Yonsei University)
Lee, Yong-ho (Department of Internal Medicine, Yonsei University College of Medicine)
Jung, Hyungil (Department of Biomaterials Science and Engineering, Yonsei University)
Publication Information
BioChip Journal / v.12, no.4, 2018 , pp. 309-316 More about this Journal
Abstract
Microneedles (MNs) are being developed to overcome the limitations of the conventional hypodermic needle, e.g. the injection pain. In this study, we conducted an analysis of clinical pain and bleeding at the site of MN insertion and evaluated the insulin pharmacodynamic profile compared with parameters obtained with a conventional pen needle. MN insertion into the skin of 25 healthy adults or 15 patients with type 2 diabetes (T2D) revealed significantly less pain relative to a conventional hypodermic pen needle, thus reducing pain scores from $2.1{\pm}1.9$ to $21.3{\pm}1.4$ ($mean{\pm}standard$ deviation [SD]). Besides, no bleeding was observed when the MN was used. In the insulin pharmacodynamic assay, no significant differences were observed in the blood glucose-lowering effect between the pen needle and MN. Based on these results, the MN is expected to be a good substitute for conventional hypodermic pen needles and improve the quality of life of patients by significantly reducing the pain associated with insulin treatment.
Keywords
Microneedle; Insulin; Subcutaneous injection; Pain; Bleeding; Pharmacodynamic profile;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Norman, J.J., Brown, M.R., Raviele, N.A., Prausnitz, M.R. & Felner, E.I. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatr Diabetes 14, 459-465 (2013).   DOI
2 Gupta, J., Felner, E.I. & Prausnitz, M.R. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol. Ther. 11, 329-337 (2009).   DOI
3 Li, C.G. et al. A Novel Ultrafine Needle (UN) for Innocuous and Efficient Subcutaneous Insulin Delivery. Advanced Functional Materials 27, (2017).
4 Pettis, R.J. et al. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabetes Technol. Ther. 13, 443-450 (2011).   DOI
5 Kochba, E., Levin, Y., Raz, I. & Cahn, A. Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. Diabetes Technol. Ther. 18, 525-531 (2016).   DOI
6 Lee, C.Y., Lee, K., You, Y.S., Lee, S.H. & Jung, H. Tower microneedle via reverse drawing lithography for innocuous intravitreal drug delivery. Adv. Healthc. Mater. 2, 812-816 (2013).   DOI
7 McKay, M., Compion, G. & Lytzen, L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: A randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol. Ther. 11, 195-201 (2009)   DOI
8 Miwa, T. et al. Comparison of the effects of a new 32-gauge x 4-mm pen needle and a 32-gauge x 6-mm pen needle on glycemic control, safety, and patient ratings in Japanese adults with diabetes. Diabetes Technol. Ther. 14, 1084-1090 (2012).   DOI
9 Lee, K., Lee, H.C., Lee, D.S. & Jung, H. Drawing lithography: three-dimensional fabrication of an ultrahigh-aspect-ratio microneedle. Adv. Mater. 22, 483-486 (2010).   DOI
10 Humphrey, M.J. The Oral Bioavailability of Peptides and Related Drugs. in Delivery Systems for Peptide Drugs (eds. Davis, S.S., Illum, L. & Tomlinson, E.) 139-151 (Springer US, Boston, MA, 1986).
11 Shaji, J. & Patole, V. Protein and Peptide Drug Delivery: Oral Approaches. Indian J. Pharm. Sci. 70, 269-277 (2008).   DOI
12 Rubin, R.R., Peyrot, M., Kruger, D.F. & Travis, L.B. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 35, 1014-1022 (2009).   DOI
13 Aronson, R. The Role of Comfort and Discomfort in Insulin Therapy. Diabetes Technol. Ther. 14, 741-747 (2012).   DOI
14 Oleck, J., Kassam, S. & Goldman, J.D. Commentary: Why Was Inhaled Insulin a Failure in the Market? Diabetes Spectr. 29, 180-184 (2016).   DOI
15 Kling, J. Inhaled insulin's last gasp? Nat. Biotechnol. 26, 479-480 (2008).   DOI
16 Mohanty, R.R. & Das, S. Inhaled Insulin - Current Direction of Insulin Research. J. Clin. Diagn. Res. 11, OE01-OE02 (2017).
17 Gill, H.S., Denson, D.D., Burris, B.A. & Prausnitz, M.R. Effect of microneedle design on pain in human subjects. Clin. J. Pain 24, 585-594 (2008).   DOI
18 Martanto, W. et al. Transdermal delivery of insulin using microneedles in vivo. Pharm. Res. 21, 947-952 (2004).   DOI
19 Gill, H.S. & Prausnitz, M.R. Coated microneedles for transdermal delivery. J. Control. Release 117, 227-237 (2007).   DOI
20 Martin, C.J., Allender, C.J., Brain, K.R., Morrissey, A. & Birchall, J.C. Low temperature fabrication of biodegradable sugar glass microneedles for transdermal drug delivery applications. J. Control. Release 158, 93-101 (2012).   DOI
21 Hameed, I. et al. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J. Diabetes 6, 598-612 (2015).   DOI
22 Fraser, R. Metabolic disorders in diabetes. Br. Med. J. 4, 591-596 (1972).   DOI
23 Nathan, D.M. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).   DOI
24 Nathan, D.M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653 (2005).   DOI
25 Thrasher, J. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. Am. J. Cardiol. 120, S4-S16 (2017).   DOI
26 CADTH Therapeutic Reviews. in Third-line Drugs for Type 2 Diabetes - Project Protocol (Canadian Agency for Drugs and Technologies in Health. Copyright (c) 2017 Canadian Agency for Drugs and Technologies in Health., Ottawa (ON), 2017).
27 McAllister, D.V. et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. Proc. Natl. Acad. Sci. USA 100, 13755-13760 (2003).   DOI
28 Gill, H.S. & Prausnitz, M.R. Pocketed Microneedles for Drug Delivery to the Skin. J. Phys. Chem. Solids 69, 1537-1541 (2008).   DOI
29 Gupta, J., Felner, E.I. & Prausnitz, M.R. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol. Ther. 13, 451-456 (2011).   DOI
30 Pettis, R.J. et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol. Ther. 13, 435-442 (2011).   DOI
31 Akkus, O., Oguz, A., Uzunlulu, M. & Kizilgul, M. Evaluation of skin and subcutaneous adipose tissue thickness for optimal insulin injection. J. Diabetes Metab. 3, 2 (2012).